Recent evidence has suggested a role for soluble oligomeric Aβ species in the pathology of Alzheimer's disease (AD). Fibrillar plaque deposits are present in non-demented individuals and levels of soluble Aβ correlate better with cognitive dysfunction in AD and transgenic mouse models. We have previously reported that there are at least two conformationally distinct types of Aβ oligomers: prefibrillar oligomers that are kinetic intermediates in fibril assembly reactions and are specifically recognized by A11 antibody and fibrillar oligomers that may represent fibril seeds or small pieces of fibrils and are recognized by a fibril specific antibody, OC. We have examined the levels of these two types of oligomers in the PBS soluble fraction of brain tissue from control cases, cases with senile degenerative changes (SDC) and AD patients. We found that the levels of soluble fibrillar oligomers detected by OC antibody are significantly elevated in multiple brain regions of AD patients. The elevated fibrillar oligomer levels were found not to be an artifact of tissue homogenization, nor a result of increased Aβ or APP levels. The concentration of fibrillar oligomers in adjacent brain regions of the same patient can vary widely and were not detected in post-mortem cerebrospinal fluid. In contrast, the level of prefibrillar oligomers are variable in both AD and age matched controls, indicating that they are not correlated with cognitive dysfunction and suggesting that they precede dementia in AD. Significant correlations were found between the levels of fibrillar oligomers and cognitive decline (MMSE scores) as well as the neuropathological hallmarks of AD. These results indicate that fibrillar oligomers may play a key role in the pathology of AD and may be a new target for diagnostic and therapeutic development.
Introduction
The genetics of inherited forms of Alzheimer's disease (AD) provides strong evidence for a causal role of Aβ, especially the faster aggregating Aβ42, in AD (Hardy, 2006; Tanzi and Bertram, 2005) . However, while some groups have reported a clear correlation between the number of Aβ plaques and dementia severity in support of this hypothesis (Blessed et al., 1968; Cummings and Cotman, 1995) , others found no such correlation (Bennett et al., 1993; McKee et al., 1991; Terry et al., 1991) . Additionally, individuals with normal cognitive function have been observed that have Aβ plaque loads that either meet or exceed the criteria for AD diagnosis (Katzman et al., 1988; Dickson et al., 1992) . These observations suggest that fibrillar Aβ may not be the primary toxic assembly state responsible for the pathology of AD. Subsequent studies of human subjects have revealed a positive correlation between soluble Aβ levels and the severity of dementia (Lue et al., 1999; McLean et al., 1999; Wang et al., 1999) , further indicating a role for soluble oligomeric species in the pathology of AD. Additional in vitro studies have reported that not only are soluble oligomers and protofibrils toxic to neuronal cell cultures (Hartley et al., 1999; Lambert et al., 1998) , but that they are more toxic than fibrils (Dahlgren et al., 2002; Kayed et al., 2003) .
The particular type of oligomer that is most closely associated with AD is a subject of considerable interest. Oligomers have been distinguished on the basis of size and elevated levels of approximately 56 kDa Aβ oligomers (ADDLs) have been identified in human brain (Gong et al., 2003) and a 56 kDa oligomer (Aβ⁎56) has been reported that is correlated with cognitive dysfunction in transgenic mouse models (Lesne et al., 2006) . Soluble dimers have been purified from human AD brain that inhibit LTP and cause cognitive dysfunction in rats (Shankar et al., 2008) . Another way of classifying oligomers is on the basis of their underlying structure, using conformation dependent antibodies (Barghorn et al., 2005; Kayed et al., 2007; Kayed et al., 2003 Kayed et al., , 2009 Lambert et al., 2001 ). These antibodies are specific for aggregated forms of Aβ and show low or no immunoreactivity against monomeric Aβ. A11, OC and αAPF recognize generic epitopes that are specifically associated with prefibrillar oligomers (A11) (Kayed et al., Neurobiology of Disease 35 (2009) 352-358 
